Citadel Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$107M Sell
490,285
-243,066
-33% -$53.9M 0.02% 768
2025
Q4
$168M Sell
733,351
-2,372,075
-76% -$540M 0.03% 568
2025
Q3
$719M Sell
3,105,426
-147,435
-5% -$30M 0.11% 115
2025
Q2
$604M Buy
3,252,861
+1,405,899
+76% +$261M 0.1% 132
2025
Q1
$387M Buy
1,846,962
+1,128,425
+157% +$219M 0.07% 193
2024
Q4
$128M Buy
718,537
+471,342
+191% +$86.7M 0.02% 606
2024
Q3
$48.8M Buy
+247,195
New +$46.1M 0.01% 1237
2024
Q2
Sell
-5,968
Closed -$989K 14132
2024
Q1
$1.09M Sell
5,968
-523,426
-99% -$90.2M ﹤0.01% 6750
2023
Q4
$82M Sell
529,394
-2,596,834
-83% -$379M 0.02% 811
2023
Q3
$466M Buy
3,126,228
+1,195,188
+62% +$175M 0.1% 109
2023
Q2
$260M Sell
1,931,040
-333,303
-15% -$48.9M 0.05% 231
2023
Q1
$361M Buy
2,264,343
+1,785,323
+373% +$273M 0.08% 154
2022
Q4
$77.4M Sell
479,020
-43,650
-8% -$6.69M 0.02% 799
2022
Q3
$70.1M Sell
522,670
-39,540
-7% -$5.67M 0.02% 811
2022
Q2
$86.1M Sell
562,210
-412,681
-42% -$63.1M 0.02% 656
2022
Q1
$158M Sell
974,891
-4,831
-0.5% -$702K 0.03% 446
2021
Q4
$133M Sell
979,722
-148,952
-13% -$17.6M 0.03% 515
2021
Q3
$122M Buy
1,128,674
+958,531
+563% +$110M 0.03% 566
2021
Q2
$19.2M Sell
170,143
-964,097
-85% -$109M ﹤0.01% 2144
2021
Q1
$123M Sell
1,134,240
-131,697
-10% -$14.1M 0.03% 493
2020
Q4
$136M Buy
1,265,937
+786,013
+164% +$75.5M 0.04% 409
2020
Q3
$42M Sell
479,924
-2,952,488
-86% -$278M 0.01% 982
2020
Q2
$337M Sell
3,432,412
-1,804,079
-34% -$159M 0.12% 85
2020
Q1
$399M Buy
5,236,491
+2,485,870
+90% +$212M 0.18% 53
2019
Q4
$244M Buy
2,750,621
+2,378,946
+640% +$197M 0.11% 133
2019
Q3
$28.1M Sell
371,675
-2,081,158
-85% -$143M 0.01% 1178
2019
Q2
$178M Buy
2,452,833
+1,810,774
+282% +$142M 0.08% 196
2019
Q1
$51.7M Buy
642,059
+622,319
+3,153% +$50.9M 0.03% 672
2018
Q4
$1.82M Sell
19,740
-1,519,899
-99% -$134M ﹤0.01% 4289
2018
Q3
$146M Sell
1,539,639
-187,012
-11% -$17.7M 0.06% 273
2018
Q2
$160M Buy
1,726,651
+1,345,279
+353% +$131M 0.08% 217
2018
Q1
$36.1M Buy
381,372
+79,718
+26% +$8.76M 0.02% 760
2017
Q4
$29.2M Buy
301,654
+135,766
+82% +$12.8M 0.02% 927
2017
Q3
$14.7M Sell
165,888
-3,504,417
-95% -$267M 0.01% 1282
2017
Q2
$266M Buy
3,670,305
+1,005,851
+38% +$67.6M 0.23% 52
2017
Q1
$174M Buy
2,664,454
+2,190,409
+462% +$138M 0.16% 90
2016
Q4
$29.7M Sell
474,045
-28,206
-6% -$1.72M 0.03% 628
2016
Q3
$31.7M Sell
502,251
-29,138
-5% -$1.89M 0.03% 614
2016
Q2
$32.9M Sell
531,389
-190,872
-26% -$11.6M 0.04% 518
2016
Q1
$41.3M Buy
722,261
+613,290
+563% +$34.2M 0.05% 374
2015
Q4
$6.46M Sell
108,971
-186,615
-63% -$10.7M 0.01% 1599
2015
Q3
$16.1M Buy
295,586
+199,957
+209% +$13M 0.02% 1031
2015
Q2
$6.42M Sell
95,629
-506,805
-84% -$33.1M 0.01% 1831
2015
Q1
$35.3M Buy
602,434
+160,187
+36% +$9.68M 0.03% 654
2014
Q4
$28.9M Sell
442,247
-373,527
-46% -$23.5M 0.03% 745
2014
Q3
$47.1M Buy
815,774
+533,331
+189% +$29.6M 0.05% 444
2014
Q2
$15.9M Sell
282,443
-240,610
-46% -$12.6M 0.02% 955
2014
Q1
$26.9M Buy
523,053
+69,479
+15% +$3.51M 0.03% 662
2013
Q4
$24M Buy
453,574
+423,161
+1,391% +$20.8M 0.03% 705
2013
Q3
$1.36M Sell
30,413
-982
-3% -$43.5K ﹤0.01% 2785
2013
Q2
$1.3M Buy
+31,395
New +$1.37M ﹤0.01% 2927

Other funds holding ABBV

Citadel Advisors's ABBV Position: Q1 2026 in Review

Citadel Advisors reduced its AbbVie (ABBV) stake by 33% in Q1 2026, selling an estimated $53.9M and leaving 490,285 shares worth $107M. The position accounts for 0.02% of the portfolio, ranked #768.

Citadel Advisors first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $719M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Citadel Advisors held 490,285 shares of AbbVie worth $107M as of Q1 2026.
  • Citadel Advisors sold 243,066 AbbVie shares in Q1 2026, an estimated $53.9M.
  • AbbVie made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #768 holding.
  • Citadel Advisors first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's AbbVie position peaked at $719M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.